Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
<p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to signific...
| 第一著者: | |
|---|---|
| その他の著者: | |
| フォーマット: | 学位論文 |
| 言語: | English |
| 出版事項: |
2021
|
| 主題: |
| _version_ | 1826307940609425408 |
|---|---|
| author | Moreira Folegatti, P |
| author2 | Gilbert, S |
| author_facet | Gilbert, S Moreira Folegatti, P |
| author_sort | Moreira Folegatti, P |
| collection | OXFORD |
| description | <p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to significantly reduce these limitations to clinical development in health emergencies.</p>
<p>Adenovirus vectors were initially developed as gene transfer vehicles for the treatment of rare genetic conditions, and over the past decade have been under investigation as a platform technology for vaccine development. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 was first evaluated in clinical trials in 2012 as a universal influenza vaccine candidate. Since then, and before this work began, ChAdOx1 vectored vaccines had been administered to 160 healthy adult volunteers as part of clinical trials of candidate vaccines against influenza, tuberculosis, and malaria.</p>
<p>This project consists of an assessment of ChAdOx1 vectored vaccines against emerging pathogens and its suitability as a platform technology for accelerated R&D and response to epidemic threats. Safety, immunogenicity, and efficacy profiles for ChAdOx1 vectored vaccines against chikungunya, Zika, MERS-CoV and SARS-CoV-2 viruses are presented here. These data have substantially contributed to the approvals of the ChAdOx1 vectored COVID-19 vaccine, now in use in over 180 countries.</p> |
| first_indexed | 2024-03-07T07:12:11Z |
| format | Thesis |
| id | oxford-uuid:5db30362-688a-4a9e-af70-ca6e76f2c26c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:12:11Z |
| publishDate | 2021 |
| record_format | dspace |
| spelling | oxford-uuid:5db30362-688a-4a9e-af70-ca6e76f2c26c2022-07-04T11:13:24ZClinical assessment of ChAdOx1 vectored vaccines against emerging pathogensThesishttp://purl.org/coar/resource_type/c_db06uuid:5db30362-688a-4a9e-af70-ca6e76f2c26cVaccine Clinical DevelopmentEnglishHyrax Deposit2021Moreira Folegatti, PGilbert, SHill, ADunachie, SShattock, R<p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to significantly reduce these limitations to clinical development in health emergencies.</p> <p>Adenovirus vectors were initially developed as gene transfer vehicles for the treatment of rare genetic conditions, and over the past decade have been under investigation as a platform technology for vaccine development. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 was first evaluated in clinical trials in 2012 as a universal influenza vaccine candidate. Since then, and before this work began, ChAdOx1 vectored vaccines had been administered to 160 healthy adult volunteers as part of clinical trials of candidate vaccines against influenza, tuberculosis, and malaria.</p> <p>This project consists of an assessment of ChAdOx1 vectored vaccines against emerging pathogens and its suitability as a platform technology for accelerated R&D and response to epidemic threats. Safety, immunogenicity, and efficacy profiles for ChAdOx1 vectored vaccines against chikungunya, Zika, MERS-CoV and SARS-CoV-2 viruses are presented here. These data have substantially contributed to the approvals of the ChAdOx1 vectored COVID-19 vaccine, now in use in over 180 countries.</p> |
| spellingShingle | Vaccine Clinical Development Moreira Folegatti, P Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title | Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title_full | Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title_fullStr | Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title_full_unstemmed | Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title_short | Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens |
| title_sort | clinical assessment of chadox1 vectored vaccines against emerging pathogens |
| topic | Vaccine Clinical Development |
| work_keys_str_mv | AT moreirafolegattip clinicalassessmentofchadox1vectoredvaccinesagainstemergingpathogens |